Stabilization of macular, peripapillary and papillary vascular parameters after XEN and trabeculectomy visualized by the optical coherence tomography angiography.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 10 2022
Historique:
received: 30 03 2022
accepted: 10 10 2022
entrez: 14 10 2022
pubmed: 15 10 2022
medline: 19 10 2022
Statut: epublish

Résumé

To analyze the effect of filtration in glaucoma surgery, XEN versus trabeculectomy, on the vessel area density (VAD) of the macular, papillary and peripapillary regions using optical coherence tomography angiography (OCT-A). This prospective cohort study analyzes the vascular architecture of 47 eyes of 45 patients after two different filtrating surgery procedures (XEN stent and trabeculectomy (TE)) using the OCT-A. Participants who had an outsourced medical anti-glaucoma therapy received filtrating surgery in a 2:1 (XEN: TE) ratio. The primary outcome measurements were changes in the VAD in various layers of retinal perfusion and the foveal avascular zone (FAZ). Both interventions achieved a significant postoperative reduction in IOP (XEN 17.6 ± 3.8-13.7 ± 3.8 mmHg; TE 21.2 ± 5.4-8.8 ± 2.6 mmHg). VAD values did not change significantly after filtrating surgery. Comparing both procedures, a significantly higher VAD for patients treated with TE was seen for the superficial vessel complex (SVC) 375 µm and 750 µm (p = 0.011, p = 0.017), deep vessel complex (DVC) 375 µm (p = 0.029) and the optic disc (p = 0.028) after 6 months, while all other parameters did not differ significantly. In conclusion, VAD does not significantly improve after filtrating surgery in preoperative moderately IOP elevated eyes. The IOP lowering effect of filtrating surgery, however, can stabilize vascular parameters in all layers of perfusion.

Identifiants

pubmed: 36241852
doi: 10.1038/s41598-022-22091-6
pii: 10.1038/s41598-022-22091-6
pmc: PMC9568588
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17251

Informations de copyright

© 2022. The Author(s).

Références

Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5993-5999
pubmed: 29183045
J Clin Med. 2020 Mar 11;9(3):
pubmed: 32168880
Transl Vis Sci Technol. 2018 Dec 06;7(6):21
pubmed: 30564510
J Glaucoma. 2001 Apr;10(2):85-8
pubmed: 11316101
Acta Ophthalmol. 2020 Sep;98(6):537-558
pubmed: 32180360
Acta Ophthalmol. 2016 Sep;94(6):592-8
pubmed: 26895610
Ophthalmology. 2017 May;124(5):709-719
pubmed: 28196732
Curr Opin Ophthalmol. 2003 Apr;14(2):106-11
pubmed: 12698052
Br J Ophthalmol. 2022 Jan;106(1):80-86
pubmed: 33153992
Invest Ophthalmol Vis Sci. 2021 Dec 1;62(15):17
pubmed: 34932063
Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1741-1750
pubmed: 31093766
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Ophthalmology. 2016 Dec;123(12):2498-2508
pubmed: 27726964
Int Ophthalmol. 2021 Aug;41(8):2677-2688
pubmed: 33782847
J Glaucoma. 2017 Jan;26(1):e7-e10
pubmed: 27571444
Ophthalmol Glaucoma. 2022 May-Jun;5(3):297-305
pubmed: 34715397
Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):983-996
pubmed: 30758653
Acta Ophthalmol. 2019 Mar;97(2):e199-e206
pubmed: 30178601
J Glaucoma. 2017 May;26(5):466-472
pubmed: 28234681
J Glaucoma. 2019 Jan;28(1):80-87
pubmed: 30461553
Graefes Arch Clin Exp Ophthalmol. 2022 Mar;260(3):957-965
pubmed: 34499247
J Ophthalmol. 2018 Jun 26;2018:8909714
pubmed: 30046465
Eye (Lond). 2012 Aug;26(8):1131-7
pubmed: 22722487
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Vestn Oftalmol. 2021;137(1):54-59
pubmed: 33610150
J Glaucoma. 2021 Jun 1;30(6):515-525
pubmed: 34060509
Am J Ophthalmol. 2002 Oct;134(4):499-512
pubmed: 12383806
Ophthalmology. 1999 Nov;106(11):2144-53
pubmed: 10571351
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4614-4621
pubmed: 30242362
PLoS One. 2021 Aug 19;16(8):e0256362
pubmed: 34411152
BMC Ophthalmol. 2020 Dec 17;20(1):490
pubmed: 33334311
Lancet Glob Health. 2021 Feb;9(2):e144-e160
pubmed: 33275949
Int J Retina Vitreous. 2019 Nov 04;5:46
pubmed: 31709114
Int Ophthalmol. 2019 Nov;39(11):2583-2594
pubmed: 31073739

Auteurs

Emanuel Reitemeyer (E)

Department of Ophthalmology, Campus Virchow- Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Milena Pahlitzsch (M)

Department of Ophthalmology, Campus Virchow- Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Anna Cornelius (A)

Department of Ophthalmology, Campus Virchow- Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Daniel Pilger (D)

Department of Ophthalmology, Campus Virchow- Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Sibylle Winterhalter (S)

Department of Ophthalmology, Campus Virchow- Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.

Anna-Karina B Maier (AB)

Department of Ophthalmology, Campus Virchow- Klinikum, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität Zu Berlin and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. anna-karina.maier@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH